Acurx director granted 37,100 stock options
Acurx Pharmaceuticals director Robert J. DeLuccia received a compensation grant of stock options covering 37,100 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Acurx Pharmaceuticals director Robert J. DeLuccia received a compensation grant of stock options covering 37,100 shares of common stock. The options were granted on April 20, 2026 with an exercise price of $2.36 per share and expire on April 20, 2036.
The options vest in 36 equal monthly installments starting on the grant date, meaning the award vests gradually over three years. Following this grant, DeLuccia holds stock options for 37,100 underlying shares directly, with no additional derivative positions shown in this filing.
Insider Trade Summary
Grant/Award: 37,100 shares
Grant/Award
1 txn
Insider
DELUCCIA ROBERT J
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 37,100 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option — 37,100 contracts (Direct)
Footnotes (1)
- F1. On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 37,100 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date.
Key Figures
Options Granted: 37,100 options
Exercise Price: $2.36 per share
Expiration Date: April 20, 2036
+3 more
6 metrics
Options Granted
37,100 options
Stock option grant to director on April 20, 2026
Exercise Price
$2.36 per share
Exercise price of granted stock options
Expiration Date
April 20, 2036
Option term for 37,100 granted options
Vesting Schedule
36 monthly installments
Equal monthly vesting starting April 20, 2026
Underlying Shares
37,100 shares
Common stock underlying the granted options
Derivative Holdings After Grant
37,100 options
Total stock options held following the transaction
Key Terms
stock options, vest, exercise price, expiration date, +1 more
5 terms
stock options financial
"the Reporting Person was granted stock options to purchase 37,100 shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
vest financial
"These options vest in 36 equal monthly installments commencing on the Grant Date"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion_or_exercise_price": "2.3600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date": "2036-04-20T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"underlying_security_title": "Common Stock""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Acurx Pharmaceuticals (ACXP) report for Robert J. DeLuccia?
Acurx Pharmaceuticals reported that director Robert J. DeLuccia received a grant of stock options for 37,100 shares. These options are a compensation award, not an open-market share purchase or sale, and give him the right to buy common stock at a fixed exercise price.
What are the key terms of the 37,100 Acurx (ACXP) stock options granted?
The grant covers options to purchase 37,100 shares of Acurx common stock at an exercise price of $2.36 per share. The options were granted on April 20, 2026 and expire on April 20, 2036, providing a long-dated right to acquire shares if exercised.
How do the newly granted Acurx (ACXP) options vest for Robert J. DeLuccia?
The granted stock options vest in 36 equal monthly installments starting on April 20, 2026. This means the award vests gradually over three years, with a portion becoming exercisable each month rather than all at once, encouraging longer-term service and alignment.
Is the Acurx (ACXP) Form 4 transaction a stock purchase or sale in the market?
No, the Form 4 transaction reflects a grant of stock options as compensation, not a market trade. The options were awarded at no cash cost per option on the grant date, with value realized only if DeLuccia later exercises them above the $2.36 exercise price.
What does Robert J. DeLuccia hold after this Acurx (ACXP) option grant?
After the grant, DeLuccia holds stock options for 37,100 underlying shares directly, according to the filing. There are no additional derivative positions shown, so this grant represents his reported derivative holdings in Acurx common stock in this particular Form 4.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates